Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Acute Lymphocytic Leukemia...
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Primary Mediastinal B-Cell...
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for B-Cell Non-Hodgkin Lymphoma....
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Follicular Lymphoma: Likelihood of Approval
CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Follicular Lymphoma. According...
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Mantle Cell Lymphoma: Likelihood of Approval
CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Mantle Cell Lymphoma....
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Diffuse Large B-Cell...